mAbxience | News
Spain’s mAbxience boosting biologics capacity with 4,000 L SUB
03/25/2021
Biosimilar maker and CDMO mAbxience will install an ABEC 4,000 L CSR bioreactor at its site in León, Spain. mAbxience, the biologics division of Spain’s Insud Pharma group, claims its León plant is “the biggest biologic plant in Spain and the first in Europe with fully integrated single-use technology in most processes.” Now the site […]
ESMO publication: EMA grants a marketing authorisation for two biosimilar medicines, bevacizumab
02/15/2021
They received a positive opinion for the treatment of carcinoma of the colon or rectum, breast cancer, NSCLC, RCC, epithelial ovarian cancer, and carcinoma of the cervix
Doctor Silvia Gold awarded Gold Medal by the Royal Academy of Medicine and Surgery of Murcia
05/20/2019
•This award is recognition of the hard work and dedication of Silvia Gold, President of the Mundo Sano Foundation, in changing the course of Chagas disease. •Mundo Sano is currently running the campaign Not a Single Baby with Chagas, to ensure that all babies and women of reproductive age have access to diagnosis and treatment. […]
Mundo Sano launches “Not a Single Baby with Chagas” initiative to change the history of Chagas disease
03/14/2019
“Not a Single Baby with Chagas” is a reflection of the Foundation’s commitment to ensuring that by 2030 all babies born with Chagas disease can be treated and cured, and that all women of reproductive age have access to diagnosis and treatment. Every hour, a baby is born somewhere in the world with Chagas disease. […]
A 3D-printed human skin dressing, a migraine predictor and a smart insulin pen: the three startups selected for support by Insud Pharma
02/18/2019
BioDan, a 3D dressing derived from human skin which can be bioprinted and frozen, Brainguard, a wearable system that predicts migraines, and Insulclock, a system which monitors and controls the treatment of diabetes patients are the three startups selected in the second round of the ChemoStart accelerator programme, which seeks to support innovative, disruptive solutions […]
Twelve startups present disruptive healthcare solutions at Insud Pharma’s Pitch Day
01/30/2019
• The ChemoStart Programme is an initiative by Insud Pharma, spearheaded by Leandro Sigman, to support innovative healthcare startups • In the second edition of the programme, 12 finalists have been shortlisted to present to a panel of experts at the Pitch Day on Thursday 31 January Madrid, 30 January 2019.- Insud Pharma’s startup […]
Publication of the final data from the clinical trial for mAbxience bevacizumab in metastatic colorectal cancer published in The Lancet Gastroenterology & Hepatology
09/27/2018
The prestigious scientific journal The Lancet Gastroenterology and Hepatology journal has published the results of the comparative study of pharmacokinetics, efficacy, safety and immunogenicity of bevacizumab biosimilar BEVZ92 in combination with FOLFOX or FOLFIRI, as the first-line treatment for metastatic colorectal cancer versus the original reference product. The trial included 15 sites from 5 countries, […]
Insud Pharma secures “very good” rating in the Profarma Programme
09/24/2018
mAbxience and the entire Insud Pharma group have once again been rated “very good” in the 2017-2020 edition of the Spanish government’s Profarma Programme, thanks to our contribution to modernising the sector, our commitment to R&D and our clear focus on activities that add value. The Programme is run by the Spanish Ministry of Economy, […]
The Autonomous University of Madrid and Insud Pharma join forces for biomedical innovation
07/16/2018
The Autonomous University of Madrid (UAM) and the multinational pharmaceutical company Insud Pharma are launching the UAM-Insud Pharma Programme of Innovation Challenges with a Strong Social Impact for biomedical innovation with an open innovation approach that enables the transfer of knowledge through science excellence to overcome some of the specific challenges of our society. This […]